Background. Blockade of the renin–angiotensin system is the primary target in the treatment
of diabetic kidney disease. Angiotensin II subtype 1 (AT1) receptor antagonists reduce …

Background Lipoprotein (a)[Lp (a)] has been well recognized as a risk factor of
cardiovascular disease. However, the association between serum Lp (a) and diabetic …

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs)
can improve dyslipidemia in patients with diabetes and albuminuria. Whether combined …

Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers
(ARBs) are frequently used for the treatment for glomerulonephritis and diabetic …

Background: End-stage renal disease (ESRD) in patients with type 2 diabetes mellitus (DM)
is associated with a bleak prognosis. The life span of patients with DM who have undergone …

Angiotensin II receptor blocker has exhibited their renal protective benefits in diabetic
nephropathy. This meta-analysis aimed to evaluate the effects of adding atorvastatin to …

Background Recently, it has been reported that urinary angiotensinogen levels is a specific
index of the intrarenal renin-angiotensin-aldosterone system (RAAS) status and it is …

Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic
proportions. Individuals with diabetes are not only more likely to develop hypertension …

Aim Albuminuria is the most important indicator of diabetic nephropathy (DN). Resveratrol, a
natural compound found in grape skins and red wine, has antioxidant effects. This study …

Abstract Aims/Introduction We aimed to evaluate the potential benefits and adverse effects of
adding a mineralocorticoid receptor antagonist (MRA) to angiotensin‐converting enzyme …